R&D Spending Showdown: Bio-Techne Corporation vs Ultragenyx Pharmaceutical Inc.

Biotech R&D: Bio-Techne vs. Ultragenyx Spending Trends

__timestampBio-Techne CorporationUltragenyx Pharmaceutical Inc.
Wednesday, January 1, 20143094500045967000
Thursday, January 1, 201540853000114737000
Friday, January 1, 201645187000183204000
Sunday, January 1, 201753514000231644000
Monday, January 1, 201855329000293998000
Tuesday, January 1, 201962413000357355000
Wednesday, January 1, 202065192000412084000
Friday, January 1, 202170603000497153000
Saturday, January 1, 202287140000705789000
Sunday, January 1, 202392493000648449000
Monday, January 1, 202496664000
Loading chart...

Data in motion

R&D Spending Trends in Biotech: A Comparative Analysis

In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Bio-Techne Corporation and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, Bio-Techne's R&D expenses grew steadily, increasing by approximately 212%, reflecting a consistent commitment to innovation. In contrast, Ultragenyx's R&D spending surged by over 1,300% during the same period, peaking in 2022. This dramatic rise underscores Ultragenyx's aggressive pursuit of groundbreaking therapies. However, data for 2024 is missing for Ultragenyx, leaving a gap in the trend analysis. As these companies continue to navigate the competitive biotech landscape, their R&D investments will likely play a pivotal role in shaping their future success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025